Evolving Practices for Myelodysplastic Syndromes (MDS): Highlights from ASH 2024 and Beyond - Episode 1

Evolving Horizons: MDS Diagnosis and Risk Stratification in 2024

, ,

The panelists discuss the newest risk stratification tool, IPSS-M.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Evolving Horizons: MDS Diagnosis and Risk Stratification in 2024
    EP. 2: MDS Treatment Strategies: From Risk Assessment to Transplantation
    EP. 3: Introducing Hypomethylating Agents for Patients With MDS
    EP. 4: ASCERTAIN Trial: Key Data of Oral Decitabine and Cedazuridine in MDS
    EP. 5: Comparison of Oral vs Intravenous Hypomethylating Agents in the Treatment of MDS
    EP. 6: Clinical Insights: Key Data Presented at ASH 2024 in MDS
    EP. 7: A Deep Dive Into Treatment Approaches for Patients With MDS by Risk Status
    EP. 8: Future Horizons in the Treatment of Myelodysplastic Syndromes

    Video content above is prompted by the following:

    • Please comment on the newest risk stratification tool, IPSS-M. Is this something you are using in practice? What is the impact of this tool in practice?
    x